FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307746163> ?p ?o ?g. }

• W4307746163 endingPage "187" @default.
• W4307746163 startingPage "175" @default.
• W4307746163 abstract "The National Institute for Health and Care Excellence (NICE) is responsible for ensuring that patients in England and Wales can access clinically and cost-effective treatments. However, NICE's processes pose significant reimbursement challenges for treatments for rare diseases. While some orphan medicines have been appraised via the highly specialised technology route, most are appraised via the single technology appraisal programme, a route that is expected to be increasingly used given new more restrictive highly specialised technology criteria. This often results in delays to access owing to differences in applicable thresholds and the single technology appraisal approach being ill-equipped to deal with the inevitable decision uncertainty. NICE recently published their updated methods and process manual, which includes a new severity-of-disease modifier and an instruction to be more flexible when considering uncertainty in rare diseases. However, as the threshold gap between the single technology appraisal and highly specialised technology programmes remains, it is unlikely that these changes alone will address the problem.We explored the potential impact of quality-adjusted life-year weights in decision making.We explored the impact of NICE's new severity-of-disease modifier weighting and two alternative methods (the use of alternative quality-adjusted life-year weights and the fair rate of return), using three recent single technology appraisals of orphan medicines (caplacizumab, teduglutide and pirfenidone for mild idiopathic pulmonary fibrosis).Our results suggest NICE's severity-of-disease modifier would not have affected the recommendations. Using alternative methods, based upon achievement of an incremental cost-effectiveness ratio below standard thresholds, patients could have received access to caplacizumab approximately 5 months earlier, and the appraisals for teduglutide and pirfenidone would have resulted in a positive recommendation following appraisal consultation meeting 1 when neither of these products was available over 5 years from the initial submission.Ultimately, moving from a restrictive end-of-life modifier to one based on disease severity is a more equitable approach likely to benefit many therapies, including orphan products. However, NICE's single technology appraisal updates are unlikely to result in faster reimbursement of orphan medicines, nor will they address concerns around market access for orphan medicines in the UK." @default.
• W4307746163 created "2022-11-05" @default.
• W4307746163 creator A5019415564 @default.
• W4307746163 creator A5039445200 @default.
• W4307746163 creator A5040933447 @default.
• W4307746163 creator A5042097123 @default.
• W4307746163 creator A5074175066 @default.
• W4307746163 creator A5083764815 @default.
• W4307746163 date "2022-10-31" @default.
• W4307746163 modified "2023-09-26" @default.
• W4307746163 title "The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products" @default.
• W4307746163 cites W1962227342 @default.
• W4307746163 cites W2089327788 @default.
• W4307746163 cites W2122317738 @default.
• W4307746163 cites W2147251987 @default.
• W4307746163 cites W2277353974 @default.
• W4307746163 cites W2317056394 @default.
• W4307746163 cites W2557128195 @default.
• W4307746163 cites W2593276100 @default.
• W4307746163 cites W2795914204 @default.
• W4307746163 cites W2890617002 @default.
• W4307746163 cites W2902615909 @default.
• W4307746163 cites W2910737538 @default.
• W4307746163 cites W2947019202 @default.
• W4307746163 cites W2982059973 @default.
• W4307746163 cites W3024347837 @default.
• W4307746163 cites W3092907813 @default.
• W4307746163 cites W3130765227 @default.
• W4307746163 doi "https://doi.org/10.1007/s41669-022-00378-8" @default.
• W4307746163 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36315388" @default.
• W4307746163 hasPublicationYear "2022" @default.
• W4307746163 type Work @default.
• W4307746163 citedByCount "0" @default.
• W4307746163 crossrefType "journal-article" @default.
• W4307746163 hasAuthorship W4307746163A5019415564 @default.
• W4307746163 hasAuthorship W4307746163A5039445200 @default.
• W4307746163 hasAuthorship W4307746163A5040933447 @default.
• W4307746163 hasAuthorship W4307746163A5042097123 @default.
• W4307746163 hasAuthorship W4307746163A5074175066 @default.
• W4307746163 hasAuthorship W4307746163A5083764815 @default.
• W4307746163 hasBestOaLocation W43077461631 @default.
• W4307746163 hasConcept C112930515 @default.
• W4307746163 hasConcept C144133560 @default.
• W4307746163 hasConcept C159110408 @default.
• W4307746163 hasConcept C160735492 @default.
• W4307746163 hasConcept C162118730 @default.
• W4307746163 hasConcept C162324750 @default.
• W4307746163 hasConcept C17744445 @default.
• W4307746163 hasConcept C177713679 @default.
• W4307746163 hasConcept C199360897 @default.
• W4307746163 hasConcept C199539241 @default.
• W4307746163 hasConcept C21333345 @default.
• W4307746163 hasConcept C2777352838 @default.
• W4307746163 hasConcept C2779256446 @default.
• W4307746163 hasConcept C2779703844 @default.
• W4307746163 hasConcept C2779951463 @default.
• W4307746163 hasConcept C3019080777 @default.
• W4307746163 hasConcept C41008148 @default.
• W4307746163 hasConcept C50522688 @default.
• W4307746163 hasConcept C60644358 @default.
• W4307746163 hasConcept C64332521 @default.
• W4307746163 hasConcept C71924100 @default.
• W4307746163 hasConcept C75480439 @default.
• W4307746163 hasConcept C86803240 @default.
• W4307746163 hasConceptScore W4307746163C112930515 @default.
• W4307746163 hasConceptScore W4307746163C144133560 @default.
• W4307746163 hasConceptScore W4307746163C159110408 @default.
• W4307746163 hasConceptScore W4307746163C160735492 @default.
• W4307746163 hasConceptScore W4307746163C162118730 @default.
• W4307746163 hasConceptScore W4307746163C162324750 @default.
• W4307746163 hasConceptScore W4307746163C17744445 @default.
• W4307746163 hasConceptScore W4307746163C177713679 @default.
• W4307746163 hasConceptScore W4307746163C199360897 @default.
• W4307746163 hasConceptScore W4307746163C199539241 @default.
• W4307746163 hasConceptScore W4307746163C21333345 @default.
• W4307746163 hasConceptScore W4307746163C2777352838 @default.
• W4307746163 hasConceptScore W4307746163C2779256446 @default.
• W4307746163 hasConceptScore W4307746163C2779703844 @default.
• W4307746163 hasConceptScore W4307746163C2779951463 @default.
• W4307746163 hasConceptScore W4307746163C3019080777 @default.
• W4307746163 hasConceptScore W4307746163C41008148 @default.
• W4307746163 hasConceptScore W4307746163C50522688 @default.
• W4307746163 hasConceptScore W4307746163C60644358 @default.
• W4307746163 hasConceptScore W4307746163C64332521 @default.
• W4307746163 hasConceptScore W4307746163C71924100 @default.
• W4307746163 hasConceptScore W4307746163C75480439 @default.
• W4307746163 hasConceptScore W4307746163C86803240 @default.
• W4307746163 hasFunder F4320307781 @default.
• W4307746163 hasIssue "2" @default.
• W4307746163 hasLocation W43077461631 @default.
• W4307746163 hasLocation W43077461632 @default.
• W4307746163 hasLocation W43077461633 @default.
• W4307746163 hasLocation W43077461634 @default.
• W4307746163 hasOpenAccess W4307746163 @default.
• W4307746163 hasPrimaryLocation W43077461631 @default.
• W4307746163 hasRelatedWork W2586098917 @default.
• W4307746163 hasRelatedWork W2811334505 @default.
• W4307746163 hasRelatedWork W2995092704 @default.

• next